S. Lau

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey et al. · The Lancet Oncology · 2020 · 599 citations · Full text

Primary Tumour Subtype, Epidemiology, Cancer Epidemiology +11

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Claire L. Cole, S. Lau, Alison Backen et al. · Cancer Biology & Therapy · 2010 · 93 citations · Full text

Heparan sulphate synthetic and editing enzymes in ovarian cancer

Alison Backen, C L Cole, S. Lau et al. · British Journal of Cancer · 2007 · 56 citations · Full text

Sulphate Groups, Cell Proliferation, Ovarian Cancer +17

Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.

S. Lau, Daniela D. Rosa, Gordon C. Jayson · PubMed · 2005 · 30 citations

Regenerative Medicine, Tumor Biology, Vegf Trap +12

The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma

Daniela Dornelles Rosa, A. Clamp, Saifee Mullamitha et al. · European Journal of Surgical Oncology · 2006 · 25 citations

Surgical Oncology, Gynecological Surgery, Medicine +6